In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
|Articles|April 19, 2021
Report: Emergent pauses J&J vaccine production at Baltimore plant
FDA launches investigation into last month’s dose contamination
Advertisement
According to a published
Emergent BioSolutions Inc, the organization that owns and runs the Baltimore plant that had been making vaccine for J&J, stated in a
J&J said it would cooperate with Emergent and FDA to address any issues following the inspection, Reuters reports.
Advertisement
Related to this article
Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
FAQ: How the GENEROUS Model Applies MFN Pricing to Medicaid
2
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
3
Why Temperature Control Is Now Pharma’s Make-or-Break Variable
4
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
5